#South Korea #Seoul #Seegene #CURECA™ #STAgora™

Seegene Unveils CURECA™ and STAgora™

Introduction to the Innovations

At the ADLM 2025 event held in Chicago from July 29 to July 31, Seegene Inc., a global leader in molecular diagnostics, introduced two groundbreaking technologies: CURECA™ and STAgora™. These advancements are set to elevate laboratory automation and infectious disease monitoring through enhanced data analysis.

CURECA™ is introduced as the first fully automated PCR diagnostic system, while STAgora™ serves as a real-time data analysis platform. Both innovations are designed to facilitate laboratory automation, optimize data analysis, and ultimately contribute to a vision of a disease-free world.

Advancements in Automation

Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, emphasized the significance of these innovations in revolutionizing diagnostics. He stated, "With CURECA™ and STAgora™, we're making a significant stride towards the future of diagnostics. Our goal is to enable laboratories worldwide to automate complex workflows while effectively utilizing diagnostic data to aid global efforts toward a world free of diseases."

Traditionally, most molecular testing systems are only partially automated and require qualified personnel for repetitive manual tasks. CURECA™ surpasses these limitations, completely redesigning global diagnostics by automating every phase of the PCR testing process, including pre-treatment, which is typically manual. Seegene asserts that achieving full automation in diagnostics hinges on three critical requirements: the ability to operate without the constant presence of highly skilled personnel, continuous operation, and the capacity to process samples without interruption. CURECA™ meets all these conditions fully.

The dedicated module, CURECA™ Prep, is capable of processing a diverse range of sample types, including urine, blood, sputum, and feces, overcoming one of the significant challenges in molecular test automation. This system completes the entire PCR workflow—from sample loading and nucleic acid extraction to amplification and result analysis—without any manual intervention.

Continuous Operation and Error Reduction

Operating continuously 24/7, CURECA™ aims to minimize human error, enhance workflow efficiency, and allow specialized staff to focus on more critical tasks. The challenge of complete automation in diagnostics is compounded by the variability of samples and the necessity for qualified staff to perform repetitive pre-treatment tasks. CURECA™ is engineered to assist laboratories in overcoming these restrictions with a scalable and flexible system adaptable to various laboratory sizes and workflows. Moreover, the CURECA™ Prep module could extend its application to other diagnostic fields such as clinical chemistry and immunodiagnostics as Seegene continues to develop increasingly advanced automation solutions.

The Role of STAgora™ in Data Analysis

STAgora™ represents the latest platform developed by Seegene, intended to collect and analyze PCR testing data in real-time, providing laboratories with a more comprehensive picture to optimize diagnostic workflows. It features over 40 analytical tools, including monitoring infection trends, tracking hospital positivity rates, and analyzing co-infection patterns from multiple pathogens. Unlike conventional data repositories, STAgora™ is designed as an integrated platform that aids laboratories in deriving meaningful insights by combining and analyzing data from various tests.

As current data from individual tests often provide limited information due to a lack of broader context, STAgora™ addresses this limitation by allowing hospitals to create custom statistical datasets and compare their data with other institutions. This capability enables quicker detection of potential infection patterns and supports more expedited decision-making. All data shared through the platform is anonymized and formatted per institutional requirements, ensuring secure and compliant exchange at local, national, and global levels.

Towards a Disease-Free World

Dr. Chun reiterated Seegene's long-term vision of contributing to the realization of a "disease-free world." The introduction of CURECA™ and STAgora™ completes the five foundational technological pillars of the company. In addition to Seegene's proprietary PCR technology and the SGDDS (Seegene Digitalized Development System) for automated test development, these new solutions join the global initiative for technology sharing, fully automated PCR testing, and advanced real-time data analysis capabilities.

Industry experts present at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of JTG Consulting Group, expressed, "Over the years, I've attended numerous ADLM conferences, and CURECA™ is one of the most innovative solutions I've seen. I believe it has the potential to streamline laboratory workflows, reduce staff workload, and significantly enhance overall operational efficiency."

In closing, Dr. Chun added, "With CURECA™ and STAgora™, we're breaking historical barriers in molecular diagnostics. Just as smartphones and electric vehicles transformed their respective industries, we believe these technologies will redefine the potentials of diagnostic testing, helping laboratories worldwide achieve genuine automation, fully leverage diagnostic data, and ultimately contribute to building a world free from diseases."